Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Brief Summary: The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.


Options:
A: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
B: Arm Label: voglibose 0.2 mg three times a day (TID); Type: ACTIVE_COMPARATOR; Interventions: Drug: voglibose | Arm Label: BI 1356 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 1356 | Arm Label: BI 1356 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 1356 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: voglibose placebo, Drug: BI 1356 placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 low dose | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 high dose | Intervention Type: DRUG; Name: voglibose placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: BI 1356 placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: voglibose; Assigned to Arm(s): voglibose 0.2 mg three times a day (TID)
C: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin
D: Arm Label: albiglutide + metformin; Type: EXPERIMENTAL; Interventions: Biological: albiglutide, Drug: metformin, Drug: placebo sitagliptin, Drug: placebo glimepiride | Arm Label: sitagliptin + metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: metformin, Biological: placebo albiglutide, Drug: placebo glimepiride | Arm Label: glimepiride + metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: metformin, Biological: placebo albiglutide, Drug: placebo sitagliptin | Arm Label: metformin + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Biological: placebo albiglutide, Drug: placebo sitagliptin, Drug: placebo glimepiride | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): albiglutide + metformin | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): sitagliptin + metformin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride + metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): albiglutide + metformin, glimepiride + metformin, metformin + placebo, sitagliptin + metformin | Intervention Type: BIOLOGICAL; Name: placebo albiglutide; Assigned to Arm(s): glimepiride + metformin, metformin + placebo, sitagliptin + metformin | Intervention Type: DRUG; Name: placebo sitagliptin; Assigned to Arm(s): albiglutide + metformin, glimepiride + metformin, metformin + placebo | Intervention Type: DRUG; Name: placebo glimepiride; Assigned to Arm(s): albiglutide + metformin, metformin + placebo, sitagliptin + metformin

Answer: C